New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory.
Jessica J Miller, Mehrdad Yazdanpanah, David A Colantonio, Daniel R Beriault, Sarah R Delaney
Clinical biochemistry December 1, 2024 DOI: 10.1016/j.clinbiochem.2024.110810 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | New psychoactive substances Unregulated drugs Urine drug testing |
| Key findings | NPS are structurally diverse and evade traditional drug detection, requiring improved toxicosurveillance for effective monitoring. |
Abstract
The production and use of New Psychoactive Substances (NPS) has skyrocketed over the last decade, causing major challenges for government authorities, public health agencies, and laboratories across the world. NPS are designed to mimic the psychoactive effects of unregulated or controlled drugs, while constantly being modified to evade drug control regulation. Hence, they are referred to as "legal highs", as they are technically legal to sell, possess, and use. NPS can be classified by their pharmacological mechanism of action and include cannabimimetic, depressants, dissociatives, hallucinogens, opioids, and stimulants. There is significant structural diversity within each NPS class, leading to variable detection using traditional clinical laboratory testing and complicating the interpretation of results. In this article, we review each of the NPS classes and summarize their associated mechanism of action, common structures, and metabolic pathways, and provide examples of recent drugs and emerging threats with a focus on Canadian drug trends. We also explore the current analytical advantages and limitations commonly faced by the clinical laboratory and provide insight on how toxicosurveillance can improve detection of NPS in the ever-changing NPS landscape.